Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says

MT Newswires Live

3 hours ago

The launch of Botanix Pharmaceuticals' (ASX:BOT) topical gel, Sofdra, performed "exceptionally well" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.

Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.

Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.

Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.

The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568944090"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568944090\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568944090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568944090","market":"us","top_or_hot":-1,"title":"Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> The launch of <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a>' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Wednesday.</p><p>Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.</p><p>Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.</p><p>Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.</p><p>The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBotanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-18 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The launch of <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a>' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a note on Wednesday.</p><p>Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.</p><p>Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.</p><p>Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.</p><p>The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BOT.AU","symbol_name":"BOTANIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568944090","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568944090","pubTimestamp":1758168019,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The launch of Botanix Pharmaceuticals'  topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BOT.AU":"BOTANIX PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7502":"大麻概念","BK7096":"制药"},"translate_title":"Euroz Hartleys表示，Botanix Pharmaceuticals推出的外用凝胶表现“非常好”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOT.AU":1},"content_text":"The launch of Botanix Pharmaceuticals' (ASX:BOT) topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}